Article
A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat.
Acta neuropathologica - 1 Nov 2011
Milde Till, Kleber Susanne, Korshunov Andrey, Witt Hendrik, Hielscher Thomas, Koch Philipp, Kopp Hans-Georg, Jugold Manfred, Deubzer Hedwig E, Oehme Ina, Lodrini Marco, Gröne Hermann-Josef, Benner Axel, Brüstle Oliver, Gilbertson Richard J, von Deimling Andreas, Kulozik Andreas E, Pfister Stefan M, Martin-Villalba Ana, Witt Olaf
Abstract excerpt
Incompletely resectable ependymomas are associated with poor prognosis despite intensive radio- and chemotherapy. Novel treatments have been difficult to develop due to the lack of appropriate models. Here, we report on the generation of a high-risk cytogenetic group 3 and molecular group C ependymoma model (DKFZ-EP1NS) which is based on primary ependymoma cells obtained from a patient with metastatic disease....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.